Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/66553
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Miller, D. | - |
dc.contributor.author | Finnie, J. | - |
dc.contributor.author | Bowden, T. | - |
dc.contributor.author | Scholz, A. | - |
dc.contributor.author | Oh, S. | - |
dc.contributor.author | Kok, T. | - |
dc.contributor.author | Burrell, C. | - |
dc.contributor.author | Trinidad, L. | - |
dc.contributor.author | Boyle, D. | - |
dc.contributor.author | Li, P. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Journal of General Virology, 2011; 92(5):1152-1161 | - |
dc.identifier.issn | 0022-1317 | - |
dc.identifier.issn | 1465-2099 | - |
dc.identifier.uri | http://hdl.handle.net/2440/66553 | - |
dc.description.abstract | A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA0) cleavage loop as a vaccine. Peptides designed across the HA0 of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA0 of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA0 of H5N1 survived homologous viral challenge, possibly because the HA0 of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA0 peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine. | - |
dc.description.statementofresponsibility | Darren S. Miller, John Finnie, Timothy R. Bowden, Anita C. Scholz, Sawyin Oh, Tuckweng Kok, Christopher J. Burrell, Lee Trinidad, David B. Boyle and Peng Li | - |
dc.language.iso | en | - |
dc.publisher | Soc General Microbiology | - |
dc.rights | © 2011 SA Pathology | - |
dc.source.uri | http://dx.doi.org/10.1099/vir.0.028985-0 | - |
dc.subject | Lung | - |
dc.subject | Animals | - |
dc.subject | Mice, Inbred BALB C | - |
dc.subject | Mice | - |
dc.subject | Orthomyxoviridae Infections | - |
dc.subject | Body Weight | - |
dc.subject | Galactosylceramides | - |
dc.subject | Protein Precursors | - |
dc.subject | Hemagglutinin Glycoproteins, Influenza Virus | - |
dc.subject | Vaccines, Subunit | - |
dc.subject | Influenza Vaccines | - |
dc.subject | Adjuvants, Immunologic | - |
dc.subject | Microscopy | - |
dc.subject | Histocytochemistry | - |
dc.subject | Viral Load | - |
dc.subject | Female | - |
dc.subject | Influenza A Virus, H3N2 Subtype | - |
dc.subject | Influenza A Virus, H5N1 Subtype | - |
dc.subject | Cross Protection | - |
dc.title | Preclinical efficacy studies of Influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1099/vir.0.028985-0 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Finnie, J. [0000-0003-2277-1693] | - |
dc.identifier.orcid | Burrell, C. [0000-0002-4020-349X] | - |
Appears in Collections: | Aurora harvest 5 Microbiology and Immunology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.